Stockscreener 앱 받기
39.65
4.39%
-1.82
전일 마감가:
$41.47
열려 있는:
$41.53
하루 거래량:
88,431
Relative Volume:
1.09
시가총액:
$113.95M
수익:
$697.00K
순이익/손실:
$-37.19M
주가수익비율:
-1.0519
EPS:
-37.6952
순현금흐름:
$-29.34M
1주 성능:
-9.99%
1개월 성능:
-26.79%
6개월 성능:
-41.61%
1년 성능:
-74.68%
1일 변동 폭
$39.21
$41.84
1주일 범위
$38.06
$44.94
52주 변동 폭
$38.06
$163.00
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
39.65 | 113.95M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-17 | 개시 | Lake Street | Buy |
| 2026-07-13 | 개시 | B. Riley Securities | Buy |
| 2026-06-16 | 개시 | Guggenheim | Buy |
| 2026-04-27 | 개시 | Craig Hallum | Buy |
| 2025-12-23 | 개시 | Oppenheimer | Outperform |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-03-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 개시 | Guggenheim | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
SPRB S-8 & SEC FilingsYahoo Finance - Yahoo! Finance Canada
Spruce Biosciences (NasdaqCM:SPRB) Stock Forecast & Analyst Predictions - Simply Wall Street
SPRB S-8 & SEC Filings - Yahoo! Finance Canada
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - BioSpace
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Business Wire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why is Spruce Biosciences stock gaining 4% today? By Investing.com - Investing.com Canada
Spruce Biosciences stock gains after analyst backs regulatory progress - Yahoo Finance
Spruce Biosciences Announces Launch of MPS3BStudy.com - Yahoo Finance
H.C. Wainwright reiterates Spruce Biosciences stock rating on BLA progress By Investing.com - Investing.com UK
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $150 - Moomoo
Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug - Fierce Biotech
Guggenheim initiates coverage on Spruce Biosciences with Buy rating - scanx.trade
Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current UpdateNon-GAAP Earnings - vinanet.vn
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com South Africa
SPRB Maintained by Guggenheim -- Price Target Lowered to $104 - GuruFocus
Guggenheim lowers Spruce Biosciences stock price target to $104 - Investing.com
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com Canada
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com UK
Guggenheim lowers Spruce Biosciences stock price target to $104 - Investing.com
Spruce Biosciences (SPRB) Climbs 5.77% to $52.64 as Momentum Builds Toward $55.27 ResistanceBPI Reversal - vinanet.vn
Spruce Biosciences (NASDAQ:SPRB) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
OrbiMed discloses 7.3% ownership of Spruce Biosciences (SPRB) common stock - Stock Titan
Spruce Biosciences | SCHEDULE 13G: Others - Moomoo
Spruce Biosciences | SCHEDULE 13G/A: Others - Moomoo
Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake - Stock Titan
Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce - Stock Titan
Spruce Biosciences | SCHEDULE 13G: Others - Moomoo
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - Stock Titan
SPRB Maintained by Citizens -- Price Target Lowered to $144 - GuruFocus
Craig-Hallum Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (SPRB) Rises 1.42% as Shares Approach Key Resistance at $49.42Extension Target - vinanet.vn
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Australia
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Nigeria
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com South Africa
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Canada
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com India
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - biospace.com
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS - MarketBeat
Spruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY - scanx.trade
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com South Africa
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com Australia
Spruce Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Spruce Biosciences, Inc. (SPRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com Nigeria
SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary - TradingView
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
스프루스 바이오 주식 (SPRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
4.22%
자본화:
|
볼륨(24시간):